{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:36:17Z","timestamp":1793295377832,"version":"4.5.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Investigational and marketed drugs for the treatment of multiple myeloma (MM) are associated with a range of characteristics and uncertainties regarding long term side-effects and efficacy. This raises questions about what matters most to patients living with this disease. This study aimed to understand which characteristics MM patients find most important, and hence should be included as attributes and levels in a subsequent quantitative preference survey among MM patients.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This qualitative study involved: (i) a scoping literature review, (ii) discussions with MM patients (<jats:italic>n<\/jats:italic> = 24) in Belgium, Finland, Romania, and Spain using <jats:italic>Nominal Group Technique<\/jats:italic>, (iii) a qualitative thematic analysis including multi-stakeholder discussions.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> MM patients voiced significant expectations and hopes that treatments would extend their lives and reduce their cancer signs and symptoms. Participants however raised concerns about life-threatening side-effects that could cause permanent organ damage. Bone fractures and debilitating neuropathic effects (such as chronic tingling sensations) were highlighted as major issues reducing patients' independence and mobility. Patients discussed the negative impact of the following symptoms and side-effects on their daily activities: thinking problems, increased susceptibility to infections, reduced energy, pain, emotional problems, and vision problems. MM patients were concerned with uncertainties regarding the durability of positive treatment outcomes, and the cause, severity, and duration of their symptoms and side-effects. Patients feared short-term positive treatment responses complicated by permanent, severe side-effects and symptoms.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> This study gained an in-depth understanding of the treatment and disease-related characteristics and types of attribute levels (severity, duration) that are most important to MM patients. Results from this study argue in favor of MM drug development and individual treatment decision-making that focuses not only on extending patients' lives but also on addressing those symptoms and side-effects that significantly impact MM patients' quality of life. This study underscores a need for transparent communication toward MM patients about MM treatment outcomes and uncertainties regarding their long-term efficacy and safety. Finally, this study may help drug developers and decision-makers understand which treatment outcomes and uncertainties are most important to MM patients and therefore should be incorporated in MM drug development, evaluation, and clinical practice.<\/jats:p>","DOI":"10.3389\/fmed.2021.686165","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T04:28:25Z","timestamp":1625545705000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative Study"],"prefix":"10.3389","volume":"8","author":[{"given":"Rosanne","family":"Janssens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamika","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Vallejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne","family":"Galinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananda","family":"Plate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Cabezudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raija","family":"Silvennoinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Coriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorina","family":"Badelita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxandra","family":"Irimia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Anttonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riikka-Leena","family":"Manninen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Schoefs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Vandebroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneleen","family":"Vanhellemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Delforge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Simoens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Huys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3389\/fphar.2019.01395","article-title":"Design, conduct, and use of patient preference studies in the medical product life cycle: a multi-method study","volume":"10","author":"van Overbeeke","year":"2019","journal-title":"Front Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s40271-017-0253-9","article-title":"Health preference research: an overview","volume":"10","author":"Craig","year":"2017","journal-title":"Patient."},{"key":"B3","unstructured":"Patient Preference Information (PPI) in Medical Device Decision-Making2020"},{"key":"B4","unstructured":"EMA Regulatory Science to 2025. - Strategic reflection2020"},{"key":"B5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/d41573-020-00032-0","article-title":"A future for regulatory science in the European Union: the European Medicines Agency's strategy","volume":"19","author":"Hines","year":"2020","journal-title":"Nat Rev Drug Discov."},{"key":"B6","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3389\/fmed.2020.00508","article-title":"Regulatory science to 2025: an analysis of stakeholder responses to the European Medicines Agency's strategy","volume":"7","author":"Hines","year":"2020","journal-title":"Front Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40271-019-00367-w","article-title":"Patient preferences in the medical product life cycle: what do stakeholders think? Semi-structured qualitative interviews in Europe and the USA","volume":"12","author":"Janssens","year":"2019","journal-title":"Patient."},{"key":"B8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3389\/fmed.2018.00285","article-title":"Patient involvement in the lifecycle of medicines according to belgian stakeholders: the gap between theory and practice","volume":"5","author":"Janssens","year":"2018","journal-title":"Front Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.drudis.2018.09.015","article-title":"Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review","volume":"24","author":"van Overbeeke","year":"2019","journal-title":"Drug Discov Today."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3389\/fphar.2019.01009","article-title":"Factors and situations affecting the value of patient preference studies: semi-structured interviews in Europe and the US","volume":"10","author":"Whichello","year":"2019","journal-title":"Front Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40258-015-0203-4","article-title":"Making good decisions in healthcare with multi-criteria decision analysis: the use, current research and future development of MCDA","volume":"14","author":"Muhlbacher","year":"2016","journal-title":"Appl Health Econ Health Policy."},{"key":"B12","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/cpt.332","article-title":"Incorporating patient preferences into drug development and regulatory decision making: results from a quantitative pilot study with cancer patients, carers, and regulators","volume":"99","author":"Postmus","year":"2016","journal-title":"Clin Pharmacol Therap."},{"key":"B13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1634\/theoncologist.2017-0257","article-title":"Individual trade-offs between possible benefits and risks of cancer treatments: results from a stated preference study with patients with multiple myeloma","volume":"23","author":"Postmus","year":"2018","journal-title":"Oncologist."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1002\/pds.4255","article-title":"MCDA swing weighting and discrete choice experiments for elicitation of patient benefit-risk preferences: a critical assessment","volume":"26","author":"Tervonen","year":"2017","journal-title":"Pharmacoepidemiol Drug Safety."},{"key":"B15","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1177\/0272989X19873630","article-title":"From individual to population preferences: comparison of discrete choice and dirichlet models for treatment benefit-risk tradeoffs","volume":"39","author":"Tervonen","year":"2019","journal-title":"Med Decision Making."},{"key":"B16","doi-asserted-by":"publisher","first-page":"50s","DOI":"10.1177\/1077558712461182","article-title":"Decision support for patients: values clarification and preference elicitation","volume":"70","author":"Llewellyn-Thomas","year":"2013","journal-title":"Med Care Res Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"Cd001431","DOI":"10.1002\/14651858.CD001431.pub5","article-title":"Decision aids for people facing health treatment or screening decisions","volume":"4","author":"Stacey","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.pec.2015.06.022","article-title":"Shared decision making: concepts, evidence, and practice","volume":"98","author":"Stiggelbout","year":"2015","journal-title":"Patient Educ Couns."},{"key":"B19","unstructured":"Advancing Use of Patient Preference Information as Scientific Evidence in Medical Product Evaluation [WebContent]. Office of the Commissioner2018"},{"key":"B20","volume-title":"Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, De Novo Requests, Inclusion in Decision Summaries Device Labeling: Guidance for Industry, Food Drug Administration Staff and Other Stakeholders","year":"2016"},{"key":"B21","volume-title":"Patient-Focused Drug Development: Collecting Comprehensive Representative Input - Guidance for Industry, Food Drug Administration Staff, Other Stakeholders - GUIDANCE","year":"2018"},{"key":"B22","first-page":"5","volume-title":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Reflection Paper on Proposed ICH Guideline Work to Advance Patient Focused Drug Development","year":"2020"},{"key":"B23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40271-019-00408-4","article-title":"Use of patient preference studies in HTA decision making: a NICE perspective","volume":"13","author":"Bouvy","year":"2020","journal-title":"Patient."},{"key":"B24","unstructured":"BouvyJ\n          Patient Preferences Studies: How NICE Aims to Make Use of Them2019"},{"key":"B25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3389\/fmed.2019.00082","article-title":"Patient preference studies during early drug development: aligning stakeholders to ensure development plans meet patient needs","volume":"6","author":"Cook","year":"2019","journal-title":"Front Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12911-019-0875-z","article-title":"Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review (accepted 23\/07\/2019)","volume":"19","author":"Janssens","year":"2019","journal-title":"BMC Med Inform Decis Mak."},{"key":"B27","doi-asserted-by":"publisher","first-page":"543046","DOI":"10.3389\/fmed.2020.543046","article-title":"Use of patient preference information in benefit\u2013risk assessment, health technology assessment, and pricing and reimbursement decisions: a systematic literature review of attempts and initiatives","volume":"7","author":"Chachoua","year":"2020","journal-title":"Front Med."},{"key":"B28","unstructured":""},{"key":"B29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40271-017-0222-3","article-title":"Giving patients' preferences a voice in medical treatment life cycle: the PREFER public-private project","volume":"10","author":"de","year":"2017","journal-title":"Patient."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s11136-009-9540-9","article-title":"Qualitative research and content validity: developing best practices based on science and experience","volume":"18","author":"Brod","year":"2009","journal-title":"Qual Life Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"622154","DOI":"10.3389\/fpubh.2021.622154","article-title":"patient preferences for lung cancer treatment: a qualitative study protocol among advanced lung cancer patients","volume":"9","author":"Durosini","year":"2021","journal-title":"Front Public Health."},{"key":"B32","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1586\/erp.10.30","article-title":"Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research","volume":"10","author":"Kerr","year":"2010","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/bjh.14193","article-title":"Multiple myeloma: practice patterns across Europe","volume":"175","author":"Raab","year":"2016","journal-title":"Br J Haematol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"R\u00f6llig","year":"2015","journal-title":"Lancet."},{"key":"B36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.6004\/jnccn.2018.0002","article-title":"NCCN guidelines insights: multiple myeloma, Version 3.2018","volume":"16","author":"Kumar","year":"2018","journal-title":"J Natl Compre Cancer Network."},{"key":"B37","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/2159-8290.CD-18-0297","article-title":"CARs versus BiTEs: a Comparison between T cell-redirection strategies for cancer treatment","volume":"8","author":"Slaney","year":"2018","journal-title":"Cancer Discov."},{"key":"B38","unstructured":"Patient Preferences in Benefit Risk Assessments During the Drug Life Cycle"},{"key":"B39","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/hec.1739","article-title":"Using qualitative methods for attribute development for discrete choice experiments: issues and recommendations","volume":"21","author":"Coast","year":"2012","journal-title":"Health Econ."},{"key":"B40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40271-019-00401-x","article-title":"Reporting formative qualitative research to support the development of quantitative preference study protocols and corresponding survey instruments: guidelines for authors and reviewers","volume":"13","author":"Hollin","year":"2020","journal-title":"Patient."},{"key":"B41","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","article-title":"Conjoint analysis applications in health\u2013a checklist: a report of the ISPOR good research practices for conjoint analysis task force","volume":"14","author":"Bridges","year":"2011","journal-title":"Value Health."},{"key":"B42","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9781316136232","volume-title":"Applied Choice Analysis","author":"Hensher","year":"2015"},{"key":"B43","article-title":"Qualitative Research Analysis","author":"Lacey","year":"2007"},{"key":"B44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/PPA.S38408","article-title":"Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis","volume":"7","author":"Hiligsmann","year":"2013","journal-title":"Patient Prefer Adherence."},{"key":"B45","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s11096-016-0257-x","article-title":"How to use the nominal group and Delphi techniques","volume":"38","author":"McMillan","year":"2016","journal-title":"Int J Clin Pharm."},{"key":"B46","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1146\/annurev.soc.22.1.129","article-title":"Focus groups","volume":"22","author":"Morgan","year":"1996","journal-title":"Ann Rev Sociol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822X05279903","article-title":"How many interviews are enough?","volume":"18","author":"Guest","year":"2006","journal-title":"Field Methods."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1177\/1049732318821692","article-title":"What influences saturation? Estimating sample sizes in focus group research","volume":"29","author":"Hennink","year":"2019","journal-title":"Qual Health Res."},{"key":"B49","first-page":"588","article-title":"Brief questions to identify patients with inadequate health literacy","volume":"36","author":"Chew","year":"2004","journal-title":"Fam Med."},{"key":"B50","unstructured":"Functional Assessment of Cancer Therapy - Multiple Myeloma"},{"key":"B51","unstructured":""},{"key":"B52","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol."},{"key":"B54","unstructured":""}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.686165\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T04:28:34Z","timestamp":1625545714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.686165\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,6]]},"references-count":54,"alternative-id":["10.3389\/fmed.2021.686165"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.686165","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,6]]},"article-number":"686165"}}